Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
IBSRELA patients reported treatment satisfaction in real-world surveyPost-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstra...
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovati...
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a missi...
Piper Sandler analyst Christopher Raymond maintains Ardelyx (NASDAQ:ARDX) with a Neutral and raises the price target from $8...
Wedbush analyst Laura Chico maintains Ardelyx (NASDAQ:ARDX) with a Outperform and raises the price target from $13 to $14.
Raymond James analyst Ryan Deschner maintains Ardelyx (NASDAQ:ARDX) with a Outperform and raises the price target from $11 t...
